Reviewing Aimmune Therapeutics (AIMT) and Its Peers
Aimmune Therapeutics (NASDAQ: AIMT) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Aimmune Therapeutics to related businesses based on the strength of its valuation, earnings, dividends, profitability, institutional ownership, analyst recommendations and risk.
This is a summary of current ratings and target prices for Aimmune Therapeutics and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aimmune Therapeutics Competitors||99||378||987||28||2.63|
Aimmune Therapeutics presently has a consensus price target of $40.00, suggesting a potential upside of 59.05%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 16.22%. Given Aimmune Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Aimmune Therapeutics is more favorable than its competitors.
Volatility and Risk
Aimmune Therapeutics has a beta of -1.04, indicating that its share price is 204% less volatile than the S&P 500. Comparatively, Aimmune Therapeutics’ competitors have a beta of 0.85, indicating that their average share price is 15% less volatile than the S&P 500.
This table compares Aimmune Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aimmune Therapeutics Competitors||-538.85%||-41.85%||-24.81%|
Institutional and Insider Ownership
72.9% of Aimmune Therapeutics shares are held by institutional investors. Comparatively, 66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 24.6% of Aimmune Therapeutics shares are held by company insiders. Comparatively, 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Aimmune Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Aimmune Therapeutics||N/A||-$106.22 million||-11.18|
|Aimmune Therapeutics Competitors||$2.57 billion||$977.16 million||1.09|
Aimmune Therapeutics’ competitors have higher revenue and earnings than Aimmune Therapeutics. Aimmune Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company’s lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.